Massachusetts Financial Services’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$386K Sell
57,480
-2,290
-4% -$18.1K ﹤0.01% 965
2026
Q1
$461K Sell
59,770
-1,587
-3% -$11.6K ﹤0.01% 898
2025
Q4
$376K Sell
61,357
-2,029
-3% -$21.9K ﹤0.01% 887
2025
Q3
$1.17M Buy
63,386
+4,169
+7% +$67K ﹤0.01% 795
2025
Q2
$770K Buy
59,217
+731
+1% +$8.64K ﹤0.01% 834
2025
Q1
$619K Sell
58,486
-1,331
-2% -$21.1K ﹤0.01% 835
2024
Q4
$1.02M Buy
59,817
+10,860
+22% +$204K ﹤0.01% 819
2024
Q3
$1.14M Buy
48,957
+10,728
+28% +$229K ﹤0.01% 790
2024
Q2
$931K Sell
38,229
-2,897
-7% -$87.9K ﹤0.01% 803
2024
Q1
$1.39M Sell
41,126
-91
-0.2% -$3.22K ﹤0.01% 759
2023
Q4
$1.3M Buy
41,217
+3,457
+9% +$82.2K ﹤0.01% 755
2023
Q3
$965K Sell
37,760
-1,447
-4% -$44.6K ﹤0.01% 765
2023
Q2
$1.12M Buy
+39,207
New +$1.07M ﹤0.01% 745
2021
Q2
Sell
-8,483
Closed -$350K 908
2021
Q1
$350K Sell
8,483
-4,945
-37% -$295K ﹤0.01% 895
2020
Q4
$583K Sell
13,428
-135
-1% -$9.14K ﹤0.01% 833
2020
Q3
$582K Buy
+13,563
New +$673K ﹤0.01% 817

Other funds holding ARCT

Massachusetts Financial Services's ARCT Position: Q2 2026 in Review

Massachusetts Financial Services reduced its Arcturus Therapeutics (ARCT) stake by 3.8% in Q2 2026, selling an estimated $18.1K and leaving 57,480 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Massachusetts Financial Services first reported a position in ARCT in Q3 2020 and has held it in 16 quarters since. The position peaked at $1.39M in Q1 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Massachusetts Financial Services held 57,480 shares of Arcturus Therapeutics worth $386K as of Q2 2026.
  • Massachusetts Financial Services sold 2,290 Arcturus Therapeutics shares in Q2 2026, an estimated $18.1K.
  • Arcturus Therapeutics made up ﹤0.01% of Massachusetts Financial Services's portfolio in Q2 2026, its #965 holding.
  • Massachusetts Financial Services first reported a position in Arcturus Therapeutics in Q3 2020 and has held it in 16 quarters since.
  • Massachusetts Financial Services's Arcturus Therapeutics position peaked at $1.39M in Q1 2024.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.